Protein biomarkers for use in lupus nephritis
AssigneesExagen Inc., The Johns Hopkins University
InventorsAndrea Fava, Michelle Petri, Sepehr Taghavi, Andrew Concoff, Jacob Vasquez, Tyler O'Malley
Life of this patent
Estimating the term…
Abstract
Methods of detecting proteins in biological samples from human patients having lupus nephritis and the use of proteins detected in biological samples to treat, diagnose, and monitor lupus nephritis and long-term kidney functional capacity in human patients.
Claims21
A method of detecting a protein in a human patient having lupus nephritis, the method comprising detecting:
- (a) an elevated level of a protein, relative to a control, in a biological sample obtained from the patient, wherein the protein comprises CD163, PRTN3, catalase, CEACAM-1, IP-10, IL-16, cathepsin S, cyclophilin A, FKBP51, S100A13, galectin-1, MMR, S100A8, CES1, nidogen-1, IL-6, CrkL, midkine, MIP-1b, tenascin C, C1q R1, PAM, PCSK9, ADAM8, CXCL16, nestin, galectin-8, or a combination of two or more thereof, and/or
- (b) a reduced level of a protein, relative to a control, in the biological sample obtained from the patient, wherein the protein comprises C5a, FOLR2, PRX1, P-cadherin, NCAM-1, IFN-gamma R1, HNMT, galectin-4, fetuin B, CRTAM, MFRP, SULTIB1, or a combination of two or more thereof.
A method of treating lupus nephritis in a human patient in need thereof, the method comprising:
- (i) detecting:
- (a) an elevated level of a protein, relative to a control, in a biological sample obtained from the patient, wherein the protein comprises CD163, PRTN3, catalase, CEACAM-1, IP-10, IL-16, cathepsin S, cyclophilin A, FKBP51, S100A13, galectin-1, MMR, S100A8, CES1, nidogen-1, IL-6, CrkL, midkine, MIP-1b, tenascin C, C1q R1, PAM, PCSK9, ADAM8, CXCL16, nestin, galectin-8, or a combination of two or more thereof, and/or
- (b) a reduced level of a protein, relative to a control, in the biological sample obtained from the patient, wherein the protein comprises C5a, FOLR2, PRX1, P-cadherin, NCAM-1, IFN-gamma R1, HNMT, galectin-4, fetuin B, CRTAM, MFRP, SULT1B1, or a combination of two or more thereof,
- (ii) administering to the human patient an effective amount of a lupus nephritis therapeutic agent.
3-128. (canceled)
A method of detecting a protein in a human patient having lupus nephritis, the method comprising detecting an elevated level of a protein, relative to a control, in a biological sample obtained from the patient, wherein the protein comprises CD163, IL-16, azurocidin, tenascin C, IL-16, catalase, thyroglobulin, S100A8, PRTN3, DBH, visfatin, DR6, DLL1, MMR, IGFBP-6, IL-6, MIP-1d, IL-1Ra, LIMP-2, Siglec-5, ANGPTL4, ESAM, MCP-1, TIM-1, TIMP-1, NOTCH-3, or a combination of two or more thereof.
Dependencies are inferred from the claim text.